Lausanne, Vaud, Switzerland · On-site
Biostatistician Intern, for Early Clinical Development in Oncology (12-months assignment) Your Mission: · Explore and apply innovative statistical methods, particularly around dose optimization, adaptive designs, and pro…
Skills: R, Python, SAS, Bayesian Statistics, Shiny Apps
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The intern will apply innovative statistical methods to dose optimization and adaptive designs within oncology clinical trials. They will collaborate with cross-functional teams to provide statistical insights and potentially develop interactive Shiny apps for monitoring.
Candidates should be recent graduates or about to graduate with a PhD or MSc in Statistics, Mathematics, or a related field. Proficiency in R is preferred, along with strong communication skills and an interest in multidisciplinary teamwork.
Your Mission:
· Explore and apply innovative statistical methods, particularly around dose optimization, adaptive designs, and probability of success assessment.
· Be part of a Clinical Trial Team and support study-level activities with your biostatistical expertise. You’ll work closely with cross-functional partners to deliver high-quality statistical insights and contribute to the planning and execution of analyses.
· Optionally: build interactive Shiny apps for dose escalation design and monitoring.
Your profile:
· About to graduate/recent graduated with a PhD in Statistics, Mathematics, or a related field, or MSc with a first research experience.
· Solid programming skills in R (preferred), with bonus points for Python or SAS.
· Strong communication skills, both written and verbal — we value clarity and curiosity!
· A collaborative mindset and a genuine interest in working in multidisciplinary teams
· A first exposure to Bayesian statistics is a plus
· A first experience building Shiny apps is a plus
· A first familiarity with oncology clinical trials is a plus
What we Offer:
· Being part of a company where innovation, collaboration, and impact aren’t just values — they’re how we work every day
· Partner with teams across disciplines, at the forefront of oncology and anti-infective development
· An inclusive and respectful workplace — proud to be Equal-Pay certified
· Grow in a culture that values people, purpose, and performance
· A chance to grow, share, and shape the future of healthcare
What to Expect in the Recruitment Process:
If your application is selected, you’ll be invited to interviews with Talent Acquisition and the Hiring Manager via Teams, followed by a panel interview and reference checks. Communication is handled via Workable—check your spam folder for emails from *@outbound.workable.com.
Please contact our HR Department prior to submitting any profiles. We cannot accept unsolicited ap-plications from agencies or recruiters
we develop for patients
Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!
Offices: Chemin Messidor 5-7, Lausanne, 1006, CH · Rue du Levant 146, Martigny, 1920 , CH
we develop for patients
Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!
Offices: Chemin Messidor 5-7, Lausanne, 1006, CH · Rue du Levant 146, Martigny, 1920 , CH
